The BRAF kinase domain promotes the development of gliomas in vivo

Genes and Cancer

Volumn 6, Issue 1-2, 2015, Pages 9-18

  Shin, Clifford H ^a,b   Grossmann, Allie H ^c,d   Holmen, Sheri L ^a,b   Robinson, James P ^e  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d ARUP LABORATORIES   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

BRAF; Glioma; Ink4a Arf; Mouse model; RCAS TVA

Indexed keywords

ARF PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE MUTATION; GLIOMA; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84949504485     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Abounader R. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev. Anticancer Ther. 2009;9:235-15.
2. Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas (Review). Int. J. Oncol. 2004;24:1101-9.
3. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DTW, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011;121:763-74.
4. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. Nature Publishing Group; 2009;28:2119-23.
5. Forshew T, Tatevossian RG, Lawson ARJ, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, Gajjar A, et al. Activation of the ERK/ MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J. Pathol. 2009;218:172-81.
6. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673-7.
7. Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, Sutton LN, Storm PB, Shaikh TH, Biegel J a. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19:449-58.
8. Tatevossian RG, Lawson ARJ, Forshew T, Hindley GFL, Ellison DW, Sheer D. MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J. Cell. Physiol. 2010;222:509-14.
9. Lawson ARJ, Tatevossian RG, Phipps KP, Picker SR, Michalski A, Sheer D, Jacques TS, Forshew T. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol. 2010;120:271-3.
10. Kaul A, Chen Y-H, Emnett RJ, Dahiya S, Gutmann DH. Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev. 2012;26:2561-6.
11. Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D, Remke M, Hartmann C, Witt H, Jones DTW, Witt O, Heiland S, Bendszus M, et al. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J. Clin. Invest. 2011;121:1344-8.
12. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop F, Lu C, Kandoth C, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 2013;45:602-12.
13. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley M-YC, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010;70:512-9.
14. Chin L, Pomerantz J, DePinho R a. The INK4a/ARF tumor suppressor: one gene--two products-two pathways. Trends Biochem. Sci. 1998;23:291-6.
15. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene. 1999;18:5311-7.
16. Robinson JP, VanBrocklin MW, Guilbeault a R, Signorelli DL, Brandner S, Holmen SL. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene. Nature Publishing Group; 2010;29:335-44.
17. Sievert AJ, Lang S, Katie L, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC, Kjetland EF, Atkins KE, Poolman EM, Evan W, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl. Acad. Sci. 2013;110:8750-8750.
18. Tatevossian RG, Tang B, Dalton J, Forshew T, Lawson AR, Ma J, Neale G, Shurtleff SA, Bailey S, Gajjar A, Baker SJ, Sheer D, Ellison DW. MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol. 2010;120:731-43.
19. Quelle DE, Zindy F, Ashmun R a, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993-1000.
20. Ivanchuk SM, Mondal S, Rutka JT. p14ARF interacts with DAXX: effects on HDM2 and p53. Cell Cycle. 2008;7:1836-50.
21. Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol. 2010;119:641-9.
22. Horbinski C, Nikiforova MN, Hagenkord JM, Hamilton RL, Pollack IF. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro. Oncol. 2012;14:777-89.
23. Holmen SL, Williams BO. Essential role for Ras signaling in glioblastoma maintenance. Cancer Res. 2005;65:8250-5.
24. Kingston RE, Chen CA, Okayama H. Calcium phosphate transfection. Curr. Protoc. Cell Biol. 2003;Chapter 20:Unit 20.3.
25. Schaefer-Klein J, Givol I, Barsov E V, Whitcomb JM, VanBrocklin M, Foster DN, Federspiel MJ, Hughes SH. The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology. 1998;248:305-11.
26. Smith EJ, Fadly A, Okazaki W. An enzyme-linked immunosorbent assay for detecting avian leukosis-sarcoma viruses. Avian Dis. 23:698-707.
27. Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney a J, Brandner S, Holmen SL. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene. Nature Publishing Group; 2011;30:1341-50.
28. Bacon C, Endris V, Rappold G. Dynamic expression of the Slit-Robo GTPase activating protein genes during development of the murine nervous system. J. Comp. Neurol. 2009;513:224-36.
29. Yang Y, Marcello M, Endris V, Saffrich R, Fischer R, Trendelenburg MF, Sprengel R, Rappold G. MEGAP impedes cell migration via regulating actin and microtubule dynamics and focal complex formation. Exp. Cell Res. 2006;312:2379-93.
30. Jones DTW, Gronych J, Lichter P, Witt O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell. Mol. Life Sci. 2012;69:1799-811.
31. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM M, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720-4.
32. Cancer T, Atlas G. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-8.
33. Kaul A, Chen Y-H, Emnett RJ, Gianino SM, Gutmann DH. Conditional KIAA1549:BRAF mice reveal brain region-and cell type-specific effects. Genesis. 2013;51:708-16.
34. Randerson-Moor J, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, Bishop DT. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 2001;10:55-62.
35. Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF. Factors Influencing the CNS Distribution of a Novel MEK 1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases. Drug Metab. Dispos. 2014;
36. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J. Pharmacol. Exp. Ther. 2013;344:655-64.
37. Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski S, Sebolt-Leopold J, Van Becelaere K, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. Elsevier Ltd; 2008;18:6501-4.
38. Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, et al. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med. Chem. Lett. 2012;3:416-21.
39. Kudchadkar R, Paraiso KHT, Smalley KSM. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 18:124-31.
40. Schnetzke U, Fischer M, Frietsch JJ, Finkensieper A, Clement JH, Hochhaus A, Rosee P La. Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: Flow cytometry loses track. Cytometry B. Clin. Cytom. 2013;17:601-3.
41. Le K, Blomain ES, Rodeck U, Aplin AE. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 2013;26:509-17.